

Index

Note: Abbreviations: LDAEP–loudness dependency auditory evoked potentials.
 All entries relate to bipolar disorder (BD), unless otherwise mentioned.

- N*-acetylaspartate (NAA) 106, 225
 late life BD 240, 241
 acetylcholinergic dysregulation, late
 life BD 240
N-acetylcysteine (NAC)
 oxidative stress reduction 55, 63,
 64, 243
 therapeutic, sensitization model
 212, 215–16
 activity, increased, Criterion A of
 DSM-5 1, 2–3
 adherence to treatment *see*
 pharmacological interventions
 adipose tissue, ‘browning’ 261–62
 adolescence *see* childhood and
 adolescence
 adrenal extracts 21
 adrenaline *see* epinephrine
 adrenocorticotrophic hormone
 (ACTH) 91, 93
 age-associated causal factors 237
 age of onset of BD 154, 220, 234–35
 age-related energy metabolism
 changes 85
 AKAP5 (A-kinase anchor
 protein 5) 149
 alcohol abuse 180, 195
 allostasis 95
 “allostatic load”/“allostatic overload”
 90, 95–96
 “allostatic state” 95
 alpha-methyl-para-tyrosine
 (AMPT) 28
 Alzheimer’s disease 85, 132,
 135, 243
 amino acids, depletion 26–27
 γ-aminobutyric acid (GABA)
 see GABA
 AMPA receptors 52, 53, 54, 156
 amphetamine(s), mania and
 animal models 13, 61–62
 catecholamine/non-catecholamine
 receptors 25
 catecholaminergic activity
 13, 25–26
 reversal, tyrosine depletion and 27
 amygdala 222
 decreased volume in BD
 late life BD 238
 pediatric BD 222
 enlarged in BD 96, 103, 106
 hyperactivity/hypertrophy 96, 155
 pediatric BD 223
 PFC connectivity 225
 responsiveness, BD vs unipolar
 depression 106–7
 stimulation, kindling 204, 209
 anhedonia 10, 11, 222
 animal models/studies 8–16
 antidepressants effect (rodents) 9
 of anxiety states 11, 15
 clock genes and BD 15, 115
 cycling behavior issue 15
 cytokines and maternal immune
 activation 122
 of depression 8, 9, 15
 behavioral 10–11
 genetic 11–13
 knock-out mice 12–13
 resident–intruder test 14
 selective breeding 11–12
 symptomatological targets 15
 GABA pharmacological
 modulation 51–52
 influenza virus exposure,
 neurodevelopment 121–22
 kindling 204, 207–8, 209
 limitations 15–16
 lithium effect on catecholamine
 activity 28
 of mania 13–16
 environmental 13–14
 facets of mania assessed 13, 16
 genetic 14–15
 pharmacological 13
 oxidative stress decrease by
 lithium 63
 requirements, of ideal
 model 8–9
 reverse translation of behavioral
 traits 13, 14, 15
 sensitization 204, 205, 207–8
 specific models
 bulbectomy 9, 10
 forced swim (Porsolt) test 9, 10
 immobility 10, 11
 knock-out mice 12–13, 14
 learned helplessness 9, 11, 212
 mild stress model 10–11
 pharmacological 13
 preference for sweet
 solutions 10, 14
 primate 10
 resident–intruder test 14
 sleep deprivation 13–14, 15
 tail suspension test (TST) 9,
 10, 11, 12
 transgenic 158
 ANK3 gene 149, 153, 154
 anterior cingulate cortex
 (ACC), in BD
 GABA levels/dysfunction 51, 52,
 54, 104
 gray matter volume 103, 108
 pediatric BD 223–24, 225
 TNF-α increase 276
 anticonvulsants 29, 251
 kindled seizure model
 206–7, 209–10
 antidepressants 26
 animal models 9, 10, 14
 glutamatergic neurotransmission 55
 HDAC inhibitors, effect on 156
 5-HT_{1A} receptor binding,
 effect 46
 late life BD 241
 mania/hypomania induced by 1,
 4–5, 14, 26, 44, 198
 melatonin levels affected by 112
 neurocognitive functioning,
 effect on 181
 operant model of action 12
 response prediction,
 LDAEPs 137
 anti-diabetic medications 263
 anti-inflammatory agents 258,
 264, 279–80
 antioxidants 61, 63

- antipsychotic drugs
 - late life BD, adherence 242
 - second generation (atypical) 260–62
 - combination therapy 263
 - in mania 251
 - metabolic effects 260–62
 - metabolic syndrome and 262–63
 - working memory impairment and 175, 181
 - anxiety disorders 5–6, 195, 196, 197
 - anxiety states, animal models (mice) 11, 15
 - “anxious distress” modifier, DSM-5 1, 5–6
 - apolipoprotein (Apo)-E4 238
 - arginine vasopressin (AVP) 91, 94
 - ARNTL1 gene 114–15, 145
 - ATF5 protein 148
 - attention deficit hyperactivity disorder (ADHD) 180, 220
 - attention/vigilance 170–71, 182
 - bottom-up processing 170, 171
 - clinical course impact 171
 - evidence for impairment in BD 171
 - measurement 171
 - mood state effect 171
 - psychotropic drug effects 181
 - top-down processing 170, 222–23
 - auditory evoked potentials, loudness dependency (LDAEP) 136–37
 - auditory mismatch negativity (MMN) 133
 - autoimmune disorders 270, 272
 - “autointoxication theory” 120
 - autoradiography, GABA system abnormalities 49–50

 - backward masking paradigm, visual 171
 - baclofen 49, 52
 - bacterial infections 123
 - bariatric surgery 264
 - basal ganglia 106, 223
 - behavior
 - animal models 8–9, 14
 - reverse translation of traits 13, 14, 15
 - deficits in BD 221–22
 - domains, for pharmacotherapy studies 250
 - metabolic syndrome and BD 260
 - behavioral sensitization 204–8
 - benzodiazepines 13, 49
 - bipolar carriers 114
 - bipolar I disorder 2, 3, 4, 8
 - cognitive traits, heritability 183
 - familial etiology 2, 237
 - melatonin suppression 112
 - bipolar II disorder, classification (DSM-IV), 4
 - “black bile” 269

 - blood–brain barrier (BBB) 270–71, 276
 - blood-oxygen level dependent (BOLD) signal 223
 - blood pressure, systolic 237
 - Bmal1 expression 115
 - body metabolic index (BMI) 261–62
 - borderline personality disorder 197
 - bottom-up processing 170, 171
 - brain
 - bottom-up/top-down processing, regions 170
 - catecholamine levels 23–24
 - cytokine access routes 271
 - development *see* neurodevelopment
 - dysfunction, insulin resistance role 260
 - free MHPG, role 23
 - function, peripheral metabolism and 259, 260
 - general intellectual functioning, regions 179–80
 - glucose metabolism in BD 104, 105
 - imaging *see* neuroimaging in BD
 - in late life BD 237, 238–40
 - learning and memory, regions 175
 - maternal immune activation and 121–22
 - in pediatric BD 222–24
 - postmortem studies *see* postmortem brain studies
 - psychoeducation effect, regions 196
 - reasoning and problem solving, regions 178
 - volume changes in BD 103
 - late life BD 238
 - neuroendocrine areas 95
 - unipolar depression *vs* 106–7
 - working memory, regions 173
 - see also specific anatomical structures*
 - brain-derived neurotrophic factor (BDNF) 150, 155, 156
 - decrease in hippocampus 210
 - defeat stress model 210
 - methylation of promotor 210
 - Val66Met polymorphism 150, 156
 - brain–metabolic axis, metabolic syndrome and BD 260
 - bromocriptine 25
 - bulbectomy, animal models 9, 10
 - buspirone 136

 - CACNB gene 149
 - calcium channel alpha 1c subunit (CACNA1C gene) 2, 149, 153, 155
 - California Verbal Learning Test (CVLT) 176
 - calorie intake, antipsychotic drugs and 261

 - cancer development analogy 215
 - candidate genes *see* gene(s), candidate
 - cannabis 156
 - CANTAB computerized
 - neurocognitive test battery 173
 - carbamazepine 52, 54, 209
 - cardiovascular disease 257, 258, 264, 276, 277
 - carers, therapy for 195
 - catalase (CAT) 61, 62, 63, 64
 - catecholamine(s) 21
 - activity reduction 26–27, 32–35
 - enzyme inhibition 27
 - precursor depletion 26–27
 - in brain 23–24
 - vs* CSF, metabolism 24
 - discovery 21–22
 - drugs depleting 21
 - drugs enhancing (and mania) 21, 24–26
 - amphetamines 25–26
 - antidepressants 26
 - dopamine agonists 25
 - L-dopa 24–25
 - yohimbine 26
 - metabolism 22–24
 - metabolites 22–23
 - in CSF 24, 28
 - major 22–23
 - minor 23
 - in plasma/urine 23–24, 28
 - postmortem brain studies 30, 31
 - storage, leakage and release 22
 - synthesis 22, 26–27
- catecholamine hypothesis of BD (CHBD) 21–35
 - evidence not supporting 28–29, 35
 - origin (of hypothesis) 21
 - supportive evidence 25, 27, 35
 - validity, direct evidence, assessment 29–32, 35
 - CSF studies 29–30
 - genetic studies 31
 - molecular neuroimaging studies 32
 - postmortem studies *see* postmortem brain studies
 - study list/summary 34
 - urine and plasma studies 29
- validity, indirect pharmacological evidence 24–29, 32–35
 - increasing catecholamine activity, effects 24–26
 - mood stabiliser effects 27–29
 - reducing catecholamine activity, effects 26–27
 - study list/summary 33 *see also* catecholamine(s), drugs enhancing; mood stabilizers

Index

- catecholaminergic system 91
 catechol-O-methyltransferase (COMT) gene *see* COMT gene
 CCL2 gene, polymorphisms 272
 CD-1 mice 11, 13–14
 celecoxib 279–80
 cell membrane, abnormalities 64–65
 central nervous system (CNS), immune dysfunction evidence 276, 280
 cerebral infarcts 238
 cerebral metabolic rate 105
 cerebrospinal fluid (CSF)
 catecholamines and metabolites in 24, 28
 evidence for catecholamine hypothesis 29–30
 lumbar vs ventricular 24
 plasma catecholamines vs 24
 GABA levels 50, 52
 serotonin metabolite (5-HIAA) levels 46
 cerebrovascular disease 236, 237
 chemokines 275
 childhood and adolescence, BD in 219–26
 behavioral deficits in BD 221–22
 cognitive control deficits 222
 face emotion labeling 221–22
 diagnosis of BD, historical controversy 219–20
 diffusion tensor imaging 224–25
 DSM-based approach 219–20, 225–26
 endophenotypes 220, 226
 functional neuroimaging 223–24
 cognitive control 224
 face emotion processing 223–24
 resting state 225
 future directions 225–26
 maltreatment, and gene methylation 94, 97, 155–56
 neurochemistry 225
 pathophysiology of BD 220–25
 phenotyping system 219–20, 226
 prevalence of BD 220
 prevention of BD 215
 “Severe Mood Dysregulation” (SMD) 219–20
 stressors 207, 210
 structural neuroimaging in BD 222–23, 225
 child sexual abuse 156
 chlordiazepoxide 13
 choline levels 109
 cholinesterase inhibitors 243
 chronic mild stress model (animal model) 9, 10–11
 chronotherapeutics in BD 115
 Chryptochrome 2 114
 circadian gene mutants 15, 145–47
 circadian locomotor output cycles kaput gene *see* CLOCK gene (human)
 circadian rhythm(s) 111–16
 abnormalities in BD 111–13, 115–16, 157
 gene association studies 15, 145–47 *see also* CLOCK gene (human)
 feedback loops 111
 hormone changes 112
 HPA axis dysfunction and cortisol 112, 196
 mechanism and regulation 111, 147
 melatonin 112
 oscillations 111–12
 primary pacemaker 111, 116
 prolactin 112
 classification *see* DSM-5; staging BD progression
 clinical staging model 278, 279
 clock gene(s) 111, 114–15, 116
 animal studies 115
 drugs influencing transcription 114, 115
 polymorphisms 114, 145
 CLOCK gene (human) 115, 145
 3111C variant (Rs 1801260) 114
 polymorphisms 114, 145
 Clock gene (mice) 15, 115, 147, 156
 CNTNAP2 gene 149
 cocaine 207–8
 CoEnzyme Q10 243
 cognition, taxonomy 170
 cognitive behavior therapy (CBT) 191–92, 193–94, 198
 BD depression vs unipolar depression 198
 mindfulness-based 194, 196–97, 199
 non-specific effects 197
 psychoeducation vs 193–94
 cognitive changes/impairment in BD 169, 180
 abnormal sleep patterns linked 113
 EEG abnormalities and 132
 elevated glucocorticoid level 95
 late life BD 234, 235–36, 239–40, 242
 NRG1 role 150
 as stage VIII (Late/End Stage) 208 *see also* neurocognitive findings in BD
 cognitive control 220–21
 deficits in BD in youth 222
 cognitive flexibility 222
 functional neuroimaging 224
 response inhibition 222, 224
 reversal learning 222, 224
 cognitive domains 170, 182
 attention/vigilance 170–71
 general intellectual functioning 179–80
 learning and memory (verbal/visual) 175–77
 reasoning and problem solving 177–79
 speed of processing 171–73
 working memory *see* working memory *see also individual domains (e.g. attention/vigilance)*
 cognitive flexibility 222
 cognitive remediation 196
 comorbidities (of BD) 5, 256
 autoimmune diseases 272
 immune dysfunction and 276–78
 late life BD 236
 metabolic syndrome *see* metabolic syndrome (MeS)
 neurological disease, treatment efficacy 242
 psychiatric illnesses 180–81
 psychotherapeutic interventions 195
 serotonin dysfunction and 46
 computed tomography (CT) 102
 COMT (catechol-O-methyltransferase) 22
 isoforms 23
 COMT gene 151, 155
 DNA methylation 155
 postmortem brain studies 30–31
 variants 31, 151
 concentration difficulties 171
 congenital learned helplessness (cLH) 11
 construct validity 8, 9, 15
 contingency tolerance, model 209–10
 continuous performance task (CPT) 171, 196
 copy number variants (CNVs) 152, 154
 glutamate receptor genes 53
 GSK-3 β 148
 corpus callosum 103, 107, 121, 240
 cortical atrophy 238
 cortical connectivity, abnormalities 135–36
 cortical plasticity, EEG and 137–38
 corticosteroid receptors 91
 corticotropin hormone (CRH) 91, 92, 93, 278
 receptor, gene polymorphism 94

- cortisol
 binding to glucocorticoid receptors 91, 92, 93–94
 circadian fluctuation 112, 196
 excess secretion/levels in BD 90, 92, 95–96, 112
 comorbidities and, link 278
 consequences 95–96
 depressive phase 92
 GR receptor number and 93–94
 in mania 92
 metabolic syndrome and BD 259–60
 mixed states 92–93
 in offspring of BD patients 93
 psychoeducation effect 196
 in remission 93
 HPA axis regulation 91
 regulation 91
 release, stress response 91 *see also* glucocorticoid(s) (GCs)
- COX2 inhibitor 279–80
 C-reactive protein (CRP) 62, 275
 Cushing's syndrome 95
 CXCL10 275
 cytidine 55
 cytokine(s) 270, 274–75
 circulating levels in BD 274–75
 mood state relationship 275
 in CSE, in BD 275
 intracellular signaling cascades 273, 274
 maternal infection and fetal neurodevelopment 122–23
 pro-inflammatory 112–13, 122, 157, 270, 280
 BD pathogenesis 270–71, 276
 brain access routes 270–71
 effect on CNS 271, 276
 elevated in BD 112–13, 122, 271, 274–75, 280
 elevated in depression 271, 274–75, 276
 environmental stressors elevating 157, 270–71
 kynurenine pathway and 157, 276, 277
 late life BD 236
 metabolic syndrome and BD 258, 259
 mRNA processing aberration 272
 therapeutic strategies 279–80
 toxicity, neuroprogression of BD and 278
 types, synthesis and “sickness behavior” 270
- secretion *in vitro*, assessment 273–74
 synthesis in CNS 276
 cytokine hypothesis, of mood disorder 270–71
- DAOA (D-amino-acid-oxidase activator, G72) 53, 147
 D-box binding protein (DBP) 15
 defeat stress 205, 210
 dehydroepiandrosterone (DHEA) 97
 dementia 236, 237–38, 241
 dentate gyrus, stress hormone effect 95–96
- depression
 animal models *see* animal models
 autoimmune disorders association 270
 cytokine elevation 271, 274–75, 276
 drugs inducing 24
 epilepsy and 131
 major *see* major depressive disorder (MDD)
 “sickness behavior” overlap 270
 unipolar *see* unipolar depression
- depression in BD 197
 assessment of therapeutics 250
 cortisol levels 92
 cytokine levels 275
 epidemiology 4
 glutamatergic abnormalities 55
 light therapy 115
 onset, stress association 90
 psychotherapeutic intervention effect 197–98
 sensitization 205
 serotonin signaling defect 43
 sleep disturbances 113
 speed of processing reduced 172
 symptoms, pathogenic mechanisms 43
 tyrosine depletion effect 27
 unipolar depression *vs* 197–98
 brain imaging 106–7
 clinical data 198
 psychotherapy 197–99
 verbal learning and memory deficits 176
 visual learning and memory deficits 177
- depressive episode
 Mixed Features specifier 1, 3–4
 short duration hypomania with 1, 4
 dexamethasone 90
 dexamethasone suppression test (DST) 92–93
 diabetes mellitus 213–14, 256, 262–63
 diacylglycerol kinase (DGKH) 148, 153, 155
- diagnosis of BD
 limitations, drug development affected by 252
 neuroimaging *see* neuroimaging in BD
 pediatric BD 219–20 *see also* under mania
- differential-reinforcement-of-low-rates 72-second (DRL 72-s) 9, 12
- diffusion tensor imaging (DTI) 103, 135
 late life BD 239
 pediatric BD 224–25
- DiGeorge syndrome 154
- di-isopropyl fluorophosphate (DFP) 11
- dimensional approaches *see* domain profiles
- DISC1/DISC2 genes 134, 151
- “Disrupted Mood Dysregulation Disorder” (DMDD) 220
- divalproex 250–51
- DNA damage
 oxidative stress causing 62
 prevention, mood stabilizers 63
- DNA methylation 155, 156, 210
 glucocorticoid receptors, child maltreatment and 94, 97
 inhibitor 210, 213
- domain profiles 252
 behavior, pharmacotherapeutic studies 250
 underuse *see* pharmacological interventions
 cognitive *see* cognitive domains
- L-dopa 22, 24–25
- DOPAL 22–23
- dopamine 21
 breakdown/metabolites 22–23
 discovery and functions 21–22
 metabolites in plasma and urine 23–24
 synthesis 22, 23–24, 26, 29
- dopamine agonists 13, 25
- dopamine receptor(s)
 D1 32, 105
 D2 32, 105
 PET/SPECT 32
 regulation, valproate action 29
- dopamine transporter (DAT) 15, 32
- DOPEGAL 22–23
- drug craving 213
- drug development 251–52
 diagnostic limitations affecting 252
 discovery and laboratory development 251–52
 limitations in 251–52
 resistance to change 252 *see also* pharmacological interventions, new

Index

- drugs of abuse
 cocaine 207–8
 manic symptoms/syndromes due to 5
 drug treatment of BD *see*
 pharmacological interventions
 DSM-III 6
 DSM-IV, 2
 bipolar II disorder, 4
 mixed episodes 4
 Not Otherwise Specified (NOS) category 5
 DSM-5, bipolar disorders and 1–6
 adolescents and children 219–20, 225–26
 aims, RDoC and 1, 2, 6
 “anxious distress” modifier 1, 5–6
 bipolar and related disorders category 1–2
 Criterion A (energy and activity) 1, 2–3
 developmental/dimensional approach 2
 development and process of 1–2
 “Disrupted Mood Dysregulation Disorder” (DMDD) 220
 earlier DSM versions *vs.*, 1, 6
 future prospects and relevance 6
 manic/hypomanic episodes diagnosis 1, 2–3
 mixed features specifier 1, 3–4
 Other Specified and Unspecified categories 1
 psychotic disorders relationship 2
 treatment-induced mania/hypomania 1, 4–5
 duration of BD 175, 182 *see also*
 staging BD progression
 dynorphin 207
 dysfunctional attitudes 198

 eating habits, poor 260
 ecstasy (MDMA) 43
 elderly, BD in *see* late life BD
 electroencephalography (EEG) 130–32
 abnormalities in BD 131–32, 138
 delta and theta activity 132
 therapeutic implications 131–32
 advantages, limitations 130
 alpha band power, treatment response and 137
 “cordance” 137
 functional integrity of white matter 135
 future developments 136–38
 cortical plasticity 137–38
 LDAEP 136–37
 pharmaco-EEG 136
 treatment response prediction 131–32, 137

 lithium effects 132
 mindfulness-based CBT effect 196–97
 normal 130–31
 principles/methods 130–31
 reduced gamma coherence in BD 135–36
 synchronous neural oscillations 135–36
 theta band and treatment response 137, 197
 electron transport chain 62, 149
 EMBLEM study 241, 242
 emotion
 ERP abnormalities and 133
 regulation 85, 197, 198
 emotional processing
 BD *vs* unipolar depression 106–7
 face processing *see* face emotion processing
 endophenotypes 9, 108
 childhood and adolescent BD 220, 226
 cognitive, chromosome 4 and 154
 late life BD and 237
 personality traits in BD 155
 sensory ERP abnormalities 134
 endoplasmic reticulum (ER) stress pathway 148–49
 endothelial cell activation, markers 62, 277
 energy, Criterion A of DSM-5 1, 2–3
 energy metabolism 85, 240
 gene association studies 146, 149
 entorhinal cortex, glutamatergic neurotransmission 53
 environmental factors, gene interaction *see* gene, environment interaction
 environmental models, of BD mania 13–14
 environmental stressors 126, 155–56, 157
 epidemiology, mixed episodes 4
 epigenetics 155–56, 210
 kindling/sensitization model 210, 211, 213, 215 *see also* gene(s), environment interaction
 epilepsy 131
 epinephrine 21
 breakdown/metabolites 22–23
 discovery 21
 metabolites in plasma and urine 23
 synthesis 22, 23
 urine/plasma levels in mania 29
 ethyl-eicosapentaenoic acid (EPA) 63, 64
 euthymia 183
 cytokine levels 275

 event-related potentials (ERPs), sensory 131
 abnormalities in BD 132–35
 clinical correlations 133–34
 early sensory processing 133
 emotional stimuli related 133
 as endophenotype 134
 mismatch negativity 133, 134, 135
 N170 and N250 response 133
 P300 132, 134, 135
 prognostic implications 134
 schizophrenia *vs* BD 134–35
 excitatory amino acid transporter-1 (EAAT1) 53
 excitatory amino acid transporter-2 (EAAT2) 53
 executive functioning 105, 107, 175, 236
 exome sequencing 152, 154
 exposure and extinction procedures 212–13
 extinction procedures 212–13

 face emotion processing (in youth) 220–21
 deficits in BD 221–22
 adult *vs* pediatric BD 223
 functional neuroimaging 223–24
 memory impairment 222
 Family Focused Treatment (FFT) 194–95
 family interventions 194–95
 Fast Fourier Transformations (FFTs) 131, 132
 DL-fenfluramine 44
 FKBP5 gene 94
 Flinders Resistant Line (FRL) rats 11
 Flinders Sensitive Line (FSL) rats 11
 flumazenil 50, 51
 fluoxetine 44
 Food and Drug Administration (FDA) 254
 forced swim (Porsolt) test (FST) 9, 10
 free radicals 61, 64 *see also* oxidative stress; reactive oxygen species (ROS)
 frontal lobe
 dysfunction, neurocognitive effects 181
 glutamatergic neurotransmission 53–54
 fronto-amygdala-striatal circuit, pediatric BD 220, 222–23, 224
 fronto-limbic activity, psychoeducation effect 196

- functional MRI (fMRI) in BD 105, 106, 130
 childhood and adolescence 223, 224, 225
 resting state 225
 limitations 226
 mindfulness-based CBT effect 197
 working memory mediation, regions 85, 105
 functional network connectivity (FNC) 197
- GABA (γ -aminobutyric acid) 49–52
 CSF and plasma levels 50, 52
 functions 49, 147
 pharmacological modulation 51–52
 animal studies 51–52
 human studies 52
 receptors *see* GABA receptors
 GABAergic dysfunction in BD 49
 autoradiography, postmortem studies 49–50
 CSF and plasma studies 50
 genetic association studies 50
 hippocampus 85
 neuroimaging 50–51
 GABA MRS 51
 neurochemical 51
 GABAergic neurons 85, 86
 gabapentin 251
 GABA receptors 49
 GABA_A 49, 51, 147
 agonists 50
 genes coding 50
 GABA_B 49
 pharmacology 49
 structures and subtypes 49
 GABA transporter, valproate effect 51–52
 GAD67 70, 71
 gender differences
 cognitive deficits in BD and 181
 late life BD 235
 gene(s)
 candidate 31, 263 *see also* gene association studies
 environment interaction 144, 155–58
 animal models 8–9
 kindling/sensitization model 210
 expression
 epigenetic control 155
 glucocorticoid receptors 93–94
 postmortem brain studies 30–31
 in stratum oriens of CA1 70, 71
 mutations in BD 144
 polymorphisms 8
 arginine vasopressin 94
 CCL2 gene 272
 circadian rhythms and 111, 114
 clock genes 114, 145
 corticotropin hormone receptor 94
 DAOA 147
 glucocorticoid receptors 90, 94
 GSK3 β 114, 148
 IL-1, in BD 272
 monoamine oxidase A 151
 serotonin (5-HT) transporter 45–46, 151
 TSPO 94–95
 weight gain and antipsychotics 262
 pro-inflammatory, overexpression 272
 gene association studies 31, 145–51
 circadian rhythm 145–47
 current evidence (list) 146
 GABAergic 50, 147
 glutamatergic 53, 146, 147
 GSK3 β /Wnt/PI3K signaling 146, 147–48
 HPA axis dysfunction in BD 94–95
 inflammation/stress response 94–95, 146, 148–49
 ion channel regulation 146, 149
 mitochondria and energy metabolism 146, 149
 monoamine metabolism 146, 151
 neurodevelopment 146, 149–51
 neurotransmitter pathways 151
 see also individual pathways/genes
 gene linkage studies 31, 145
 general intelligence (“g”) 179
 see also intellectual functioning, general
 genetic engineering 8
 genetic factors in BD etiology 144–59, 252, 271
 association studies *see* gene association studies
 future directions 158–59
 linkage studies 31, 145
 summary 156–58
 whole-genome approaches 151–56
 epigenetics *see* gene(s), environment interaction
 findings (summary) 152
 GWAS *see* genome-wide expression studies
 pharmacogenomics 156
 quantitative trait loci 154–55
 structural variants (CNVs) 152, 154
 genetics 2
 animal models and 8
 of depression 11–12
 of mania 14–15
 BD mechanism 35
 catecholamine hypothesis, evidence for 31
 glutamatergic neurotransmission and 53
 late life BD 237, 238
 lithium response 156
 polygenic disorder, BD as 144
 genome-wide expression studies 31, 153, 154
 catecholamine hypothesis and brain tissue 31
 GABA genes and BD 50
 glutamatergic neurotransmission 53
 inflammation/stress response role 148
 lithium response 156
 geriatric BD *see* late life BD
 Germany, BD severity 210–12
 germ theory of disease 120
 glial cells 103, 104
 glucocorticoid(s) (GCs)
 “allostatic load”/“overload” 90, 95–96
 “allostatic state” 95
 chronic elevation 95, 278
 amygdala changes 96
 cognitive impairment 95
 failure to recover from, chronic disorders 97
 hippocampus changes 95–96
 neuroinflammatory effects 96
 neuronal damage mechanism 96–97
 neuroplasticity 95–96
 prefrontal cortex changes 96
 white matter changes 96
 stress and inflammatory response interplay 96–97
 stress response 91, 278 *see also* cortisol; dexamethasone
 glucocorticoid receptors (GRs) 90, 91, 92, 93–94
 antagonists 97
 co-factors and signaling changes 94, 96
 cortisol binding mechanism 92
 gene expression and receptor number 93–94
 gene methylation, child maltreatment and 94, 97
 gene polymorphisms 90, 94
 hippocampal microglia, stress-induced activation 96
 isoform abnormalities in BD 93–94
 NR3C1 gene 94, 97
 YWHAH gene 94
 glucose metabolism, brain 104

Index

- glutamate 52–55, 106, 157
 functions 52
 levels, treatment response
 prediction 109
 peripheral uptake 54
 glutamate receptor(s) 52
 antagonist 243
 GluR5 54
 GluR6 14
 GluR7 53
 pharmacology 52
 glutamatergic neurotransmission
 abnormalities 52–55, 147, 236
 evidence supporting hypothesis 147
 genetics and 53, 146, 147, 154
 exome sequencing, “hub”
 genes 154
in vivo studies 54
 blood-based analyses 54
 neuroimaging 54
 pharmacological modulation 54–55
 antidepressants 55
 mood stabilizers 54–55
 postmortem studies 53–54
 entorhinal cortex 53
 frontal cortex 53–54
 hippocampus 53
 medial temporal cortex 53
 striatum 53
 glutamic acid decarboxylase (GAD) 50
 glutamine 70
 glutathione 54, 240
 depletion 55
 glutathione reductase (GR) 62
 glutathione S-transferase (GST) 62
 glycine 54
 glycogen, metabolism in GABA
 neurons 86
 glycogen synthase kinase-3 β (GSK-3 β)
see GSK-3 β
 glycolysis 72, 74, 85, 86, 88
 genes involved 71, 72
 G protein, overactivation 65
 GPx, unipolar depression 64
 gray matter
 increased volume, lithium effect 240
 reduced volume 120, 278
 GRIN2B 53
 GRM3 gene 53
 GRM7 gene 53
 growth hormone 112
 GSK-3 86
 inhibition by lithium 55, 251
 GSK-3 β 114
 circadian clock regulation 114,
 147, 156
 copy number variation 148
 gene association studies 146, 147–48
 gene polymorphism 114, 148
 genetic animal models 14–15
 lithium inhibiting 114, 115, 147, 156
 lithium response and 156
 mice lacking gene 148
 transgenic mice overexpressing
 115, 148
 health, physical/mental,
 interaction 256
 herpes simplex virus type 2 (HSV-2)
 123, 125
 high anxiety bred (HAB) mice 11
 high-risk populations,
 neuroimaging 108–9
 hippocampus
 age-related changes in energy
 metabolism 85
 BDNF decrease 210
 CA1 stratum oriens
 feedback inhibition of CA3
 interneurons 87, 88
 feed-forward excitation by
 CA3/2 87, 88
 GABA cells, metabolism
 85, 86
 GAD67 70, 71
 gene expression upregulated
 70, 71, 72
 hypermetabolism *see below*
 metabolic pathways and 85, 86
 protein synthesis upregulation 70
 CA3/2 stratum oriens 70
 abnormalities in psychotic
 illness 86
 feedback inhibition by CA1 87, 88
 feed-forward excitation of CA1
 pyramidal cells 87, 88
 functions 88
 GABAergic tone disturbances 86
 CA3 region
 lithium effect 96
 neuron changes due to stress
 hormones 95–96
 circuitry 87
 circuitry-specific
 hypermetabolism 70–88
 background to 71
 discussion of results 85–88
 gene clusters/GenMapp
 clusters 71, 72
 individual genes/GenMapp
 74, 79, 82
 methods (study) 71
 mRNA gene clusters 85
 NADH-ubiquinone
 oxidoreductase 85
 results (study) 71–85
 ribosomal proteins 82
 synaptic plasticity cluster 79
 synaptic transmission
 cluster 71, 79
 translation factors 82
 tRNA synthetases 82
 GABAergic interneurons and
 85, 86
 glucocorticoid receptor numbers 93
 glutamatergic neurotransmission 53
 learning and memory 175
 maternal influenza virus infection
 effect 121–22
 microglial immunophenotype
 changes 96
 neuroinflammatory effects of stress/
 glucocorticoids 96
 NMDA receptor 53, 95–96, 147
 stress hormone effect,
 neuroplasticity 95–96
 volume change in BD 104, 106,
 108, 240
 glucocorticoid elevation
 (chronic) 95–96
 histone deacetylase (HDAC) inhibitor
 156, 213, 251
 histone modification 155, 210
 homeostasis 91
 homocysteine 240
 homovanillic acid (HVA) 23, 29–30
 hormones
 late life BD 240
 stimulated by serotonin 44
 hospitalization
 verbal memory impairment and
 176, 182
 working memory impairment
 and 174–75
 HPA axis *see* hypothalamic–pituitary–
 adrenal axis (HPA)
 H/Rouen mice 11
 5-HT *see* serotonin
 5-HT_{1A} receptors 45, 106
 agonists 11
 animal models 11, 12
 antidepressant treatment effect 46
 binding in BD 45
 EEG frequency spectrum and
 buspirone 136
 functions and mechanism 45
 LDAEP 136–37
 role in depression 12, 45
 somatodendritic 136–37
 suicidal attempts and 45 *see also*
 serotonin; serotonin signaling
 dysfunction
 5-HT_{2A} receptor, blockade 44, 261
 5HTTLPR gene 45–46
 5-HT transporter *see* serotonin
 transporter (5-HT transporter)
 “humors” 269
 5-hydroxyindoleacetic acid
 (5-HIAA) 46
 3-hydroxykynurenine (3-HK) 274

- 5-hydroxytryptamine (5HT) *see* serotonin
- hyperactivity,
 pharmacologically induced in animals 13
- hyperarousal symptoms, adolescence and childhood 219
- hypercortisolemia *see* cortisol, excess secretion/levels in BD
- hypermetabolism, circuitry-specific *see under* hippocampus
- hypomania/hypomanic episodes 197
 diagnosis/classification (DSM-5)
 energy/activity increased 1, 2–3
 mixed features specifier 1, 3–4
 duration criteria 4
 short duration with depressive episodes 1, 4
 symptoms 5
 treatment-induced, DSM-5 and 1, 4–5
- hypothalamic–pituitary–adrenal axis (HPA) 90, 278
 abnormalities in BD 92–93, 112, 278
 abnormal activation 278
 circadian rhythms and 112, 196
 depressive phase 92
 enduring changes 93, 278
 gene association studies 94–95
 gene polymorphisms 94
 mania 92
 mixed states 92–93
 offspring of BD patients 93
 remission 93, 112
 blunted response to serotonin agents 44
 dexamethasone suppression test 92
 glucocorticoid receptors (GRs) and 90, 93–94 *see also* glucocorticoid receptors (GRs)
 glucocorticoid (GC) release 91
 metabolic syndrome and BD 259–60
 regulation 91
 stress response *see* stress response
- hypothalamus, catecholaminergic input 91
- ICAM (intracellular adhesion molecule) 275, 277
- immobility, animal models/tests 10, 11, 12
- immune dysregulation in BD 269–80
 clinical comorbidities and 276–78
 cortisol role 278
 inflammation role 277
 drugs affecting 279
 evidence 271–75, 280
 autoimmune diseases 272
 in CNS 276, 280
- cytokines secretion *in vitro* 273–74
- immune marker levels (circulating) 274–75
- immune-related genes 271–72
- intracellular signaling cascades 273, 274
- peripheral blood mononuclear cells 272–73, 280 *see also* cytokine(s)
- neuroprogression in BD 278
- immune system 269–70
 BD treatment strategies based on 279–80
- maternal immune activation 121, 122–23, 126
- impulsivity 134
- indoleamine 2,3-dioxygenase (IDO) 259
- infectious agents/infections 120–26
 BD and 120–26
 “autointoxication theory” 120
 historical background 120–21
 maternal exposure, neurodevelopment 121–23, 126
 vs unipolar disorders 126
 depressive symptoms associated 270
 future prospects 126
 mood disorders and 124–26
 adult populations 125–26
 risk after childhood infections 125
 risk in offspring after maternal infection 124–25
 schizophrenia/schizoaffective disorders and 123–24
 adult populations 124
 risk after childhood infections 123–24
 risk in offspring after maternal infections 123
 as stressor, BD and schizophrenia risk 126
- inflammation/inflammatory response 269
 activators/activation 269–70
 in BD 112–13, 148–49, 258–59
 cytokines and 112–13, 121–22, 157, 258, 259
 gene association studies 94–95, 146, 148–49
 late life BD 236
 metabolic syndrome and 258–59, 277
 neuroprogression 278
 stress and glucocorticoids interplay 96–97
- chronic 270
- components 269
- mood changes/symptoms and 270–71
 mechanisms 259
- mood disorder pathogenesis 258–59, 270
- obesity and 259
- inflammatory disorders 258–59
- inflammatory mediators 269, 275
 effect on CNS functions 276 *see also* cytokine(s)
- influenza virus, maternal infection 120
- mood disorder risk in offspring 124–25
- neurodevelopmental effects and BD 120, 121–22, 126
- schizophrenia risk in offspring 123
- vaccine, BD preventive role 126
- insula, anterior, activation 85
- insulin, resistance 260
- intellectual functioning, general 179–80, 182
 clinical course impact 180
 evidence for impairment in BD 180
 mood state effect 180
- inter-alpha-trypsin-inhibitor gene family 148, 153
- interferon- α (IFN- α) 270
- interferon- γ (IFN- γ) 270, 271, 273
- interleukin-1 (IL-1) 270, 272
- interleukin-1Ra gene (IL1RN) 272
- interleukin-1 β (IL-1 β) 122, 272, 275, 276, 278
- interleukin-2 (IL-2) 273
- interleukin-6 (IL-6) 112, 122, 273, 275
- interleukin-10 (IL-10) 273, 276
- interpersonal and social rhythm therapy (IPRST) 192–93, 198
- intracellular signaling *see* signaling cascades
- intrinsic functional connectivity (iFC) 225
- ion channel regulation 157
 gene association studies 146, 149, 154
- ionotropic receptors, glutamate 52
- IQ (intelligence quotient) 180
 clinical course impact 180
 mood state effect 180
- irritability, severe/chronic 219, 220
- isoprostanone 64
- kainate receptors 52, 53, 147
 frontal cortex 54
 hippocampus 53
 mood stabilizers effect 54
 striatum 53
- Kaplan–Meier survival analysis 252, 253
- ketamine 55
- ketoconazole 97

Index

- kindling/sensitization (K & S)
 model 204–16
 animal studies 207–8
 anticonvulsant drug effect 206–7
 BD severity in US vs Netherlands/
 Germany 210–12
 behavioral sensitization vs 205
 contingent tolerance to
 anticonvulsants 209–10
 reversal of tolerance 209–10
 cross sensitization of stressors
 208–9, 210–11, 215–16
 description 204
 electrical, spatiotemporal
 spread 208
 epigenetics 210, 211, 213, 215
 evidence against role 206
 evidence for role in BD 205–6, 207,
 215
 from illness course 209
 future prospects 213–15
 historical overview 204–7
 neurobiology and 209, 213, 215
 non-specific mechanisms of BD
 progression 213
 pathophysiological mechanisms
 210, 215
 phenomena in affective
 disorders 205–6
 psychopharmacological
 paradigms 209–10
 seizures 204, 206–7, 208, 209
 stages of BD 208–9
 interventions effect 206, 209, 214
 therapeutic approaches based
 on 209–10
 treatment implications 211–13
 N-acetylcysteine 212, 215–16
 non-pharmacological 212–13
 see also sensitization
 knockdown (KD) mouse line 15
 knockout mice 12–13, 14
 Krebs cycle 72, 74, 85–88
 genes involved 71, 72
 kynurenine-3-monooxygenase
 enzyme (KMO) 276, 277
 kynurenine pathway 157, 274, 276, 277

 lamotrigine 251
 glutamatergic neurotransmission 55
 late life BD 242
 mechanism of action 29
 oxidative stress decrease 63
 late life BD 234–43
 biological mechanisms 236–38
 age-associated causal factors 237
 genetics/heritability 237
 neurodegeneration 237–38
 psychosocial factors 238
 vascular factors 237
 clinical aspects 234–36
 cerebrovascular disease and 236
 clinical features 235
 comorbidity 236
 course and relapse/
 recurrence 235
 differential diagnosis 235
 epidemiology 234–35
 neurocognitive findings 235–36
 cognitive impairment 234,
 235–36, 239–40
 future prospects 242–43
 historical perspective 234
 hormones, neurotransmitters and
 nutrients 240
 laboratory measures 238–40
 acute efficacy of drugs 242
 genetic variation 238
 pharmacotherapeutics
 and 240–42
 side effects of drugs 241
 mortality 236
 neuroimaging 238–40
 brain morphology, cognitive
 deficits 239–40
 diffusion tensor imaging 239
 functional neuroimaging 239
 MRS 240
 volumetric findings 238
 white matter
 hyperintensities 238–39
 pathophysiology, models 237
 pharmacodynamics 241–42
 acute efficacy 241
 continuation/maintenance
 efficacy 242
 modifiers of acute
 efficacy 241–42
 modifiers of long-term
 outcomes 242
 side effects/tolerability 241
 pharmacokinetics 241
 pharmacotherapeutics 240–42
 novel treatments 243
 learned helplessness, animal model 9,
 11, 212
 learning and memory 175–77
 brain lesions (left/right) 175
 organizational dysfunction 175
 reversal learning, impairment
 222, 224
 verbal 175, 182, 235
 alcohol abuse comorbid
 with BD 180
 clinical course impact 176
 encoding and retrieval
 deficits 175–76
 evidence for impairment in
 BD 175–76
 mood state effect 176, 182
 psychotropic drug effects 181
 recognition deficits 176
 visual 175, 182
 clinical course impact 177
 evidence for impairment
 in BD 177
 mood state effect 177
 levodopa (L-dopa) 22, 24–25
 lidocaine, seizures induced 207, 208
 life expectancy 213
 lifestyle management 263, 264
 light/dark cycles 111–12
 light therapy 115
 limbic system
 BD vs unipolar depression 105,
 106–7
 5-HT_{1A} receptors 106
 lipid peroxidation 61–62
 cell membrane damage and 65
 prevention, mood stabilizers 63
 lipopolysaccharide (LPS) 121–22,
 270, 273
 lithium 8, 191
 beneficial effects on brain
 integrity 243
 CA3 pyramidal cell structure 96
 early initiation 214
 effect on clock genes 115
 effects on catecholamine
 activity 28–29
 animal studies 28
 human studies 28–29
 effects on EEG 132
 effects on neuroimaging in late
 life BD 240
 GABA levels
 animal studies 52
 human studies 52
 glutamatergic neurotransmission 54
 GSK-3 inhibition 55, 251
 GSK-3 β inhibition 114, 115,
 147, 156
 mechanism of action 28
 neurocognitive functioning,
 effect on 181
 neurotoxicity 132
 oxidative stress decrease 63
 response 156
 continuation/maintenance
 efficacy 242
 EEG abnormalities and 131–32
 genetics 156
 modifiers of acute efficacy 242
 tolerability in late life 241
 locus ceruleus 104
 long-term potentiation (LTP) 137–38
 loudness dependency auditory evoked
 potentials (LDAEP) 136–37
 low-anxiety bred (LAB) mice 11
 lymphocytes in BD 272–73

- machine learning classification 226
 “macrophage theory of depression” 270
 magnetic resonance imaging (MRI) 102
 in BD, findings and variations in 102–3, 135
 late life BD 238
 pediatric BD 222–23
 magnetic resonance spectroscopy (MRS) 106
 GABA 51, 52
 late-life BD 240, 241
 pediatric BD 225
 magneto-encephalography (MEG) 130
 major depressive disorder (MDD)
 depression in BD vs, cortisol levels 92
 glucocorticoid receptor numbers 93
 HPA axis changes and 90
 serotonin-based medications 43–44
 short-duration hypomania and 4
 sleep disturbances 113
 stroke association 237
 major histocompatibility complex (MHC) 122–23, 148
 malondialdehyde (MDA) 64, 65
 mania 197
 animal models *see* animal models
 assessment of therapeutics 250
 attention impairment 171
 cerebral metabolic rate 105
 cerebrovascular disease association 236
 cortisol levels 92
 cytokine levels 275
 dark exposure and 115
 diagnosis/classification (DSM-5) 1, 2–4
 differential diagnosis 235
 as first episode, late life 234, 235
 melatonin levels 112
 premature mortality 71
 pro-inflammatory gene expression 272
 “secondary”/“symptomatic” 237
 serotonin signaling changes 43
 sleep deprivation/decreased need 113
 speed of processing reduced 172
 symptoms 43
 treatment
 atypical antipsychotics 251
 serotonin-based antidepressants 44
 tyrosine depletion 27
 treatment-induced 44, 198
 animal models 13, 14
 antidepressants 1, 4–5, 14, 26, 44, 198
 DSM-5 classification and 1, 4–5
 L-dopa 24 *see also*
 catecholamine(s), drugs enhancing
 urine levels of catecholamines 29
 verbal learning and memory deficits 176
 visual learning and memory 177
 “manic depressive insanity” 234
 maternal immune activation (MIA) 121, 122–23, 126
 maternal infections *see* infectious agents/infections
 MATRICS initiative 170, 177
 medial temporal cortex, glutamatergic neurotransmission 53
 melatonin 112, 115
 antidepressants effect 112
 therapeutic, in metabolic syndrome and BD 263
 memory
 declarative 95, 175 *see also* learning and memory
 encoding and retrieval 175
 impairment, for emotional faces 222
 working *see* working memory
 metabolic dysfunction 256–64
 metabolic syndrome (MeS)
 256, 258–60
 associated disorders 256
 BD comorbidity/interactions 256, 257, 258, 277
 BD presentation and features 256–57
 BD prevalence 256, 258
 iatrogenic/non-iatrogenic 257, 258
 preventive strategies for MeS 262–63
 screening for MeS 262–63
 screening for mood disorders 263
 treatment resistance 256, 258
 treatment strategies 263–64
 BD interaction mechanisms 258–60
 brain-metabolic axis 260
 health behaviors linking 260
 HPA axis dysfunction and 259–60
 inflammatory 258–59, 277
 obesity and 259, 260
 second generation antipsychotics and 262
 clinical/biochemical features 256, 257
 prevalence 256, 258
 risk factors 256, 258
 metabolism
 brain function relationship 259, 260
 circuitry-specific hypermetabolism *see under* hippocampus
 energy *see* energy metabolism
 glucose, brain 104
 glycogen, in GABA neurons 86
 second generation antipsychotic effects 260–62
 tryptophan, kynurenine pathway 276, 277
 metabotropic receptors, glutamate 52, 147
 metanephrine 23
 methylation *see* DNA methylation
 metyrapone 97
 MHPG (3-methoxy-4-hydroxyphenylglycol) 22
 in CSF 24, 29–30
 free, release rate 23
 level reduced by lithium 28
 in plasma and urine 23, 29
 microarray analyses 70, 71
 microglial cells 276
 overactivity 259, 276
 mifepristone 97
 mindfulness-based cognitive behavior therapy (CBT) 194, 196–97, 199
 mineralocorticoid receptors (MR) 91, 93–94
 mitochondrial dysfunction 65, 157
 in BD 62, 65, 153
 gene association studies 146, 149
 gene deletions/SNPs 149
 in brain disorders 70
 in schizophrenia 149
 mitogen-activated protein kinase (MAPK) 273, 274
 mixed episodes/states 8
 cortisol levels 92–93
 DSM-IV 4
 DSM-5 1, 3–4
 in late life 234
 symptoms 3, 4
 models, animal *see* animal models
 monoamine oxidase (MAO) 22
 monoamine oxidase A (MAOA), gene polymorphisms 151
 monocytes 273, 274
 mood disorders
 cytokine hypothesis 270–71
 infectious agents association *see* infectious agents
 inflammatory pathogenesis 258–59, 270
 in late life, historical aspects 234
 mood disorder specialty clinic 192

Index

- mood stabilizers 8
 acute efficacy in late life BD 241, 242
 effects on catecholamine activity 27–29
 GABA levels 52
 glutamatergic neurotransmission 54–55
 5-HT_{2A} receptor blockade 44
 intracellular signaling affected by 55
 late life BD 243
 oxidative stress decrease 63
 resident–intruder test on animals and 14
 selective efficacy 250–51 *see also* lamotrigine; lithium; valproate
 mortality in BD 70, 71, 258, 276–77
 late life BD 236
 multiple sclerosis analogy 206
 Multistate Outcome Analysis of Treatments (MOAT) 252–53
 muscarinic M2 receptors 106
 myo-inositol 106, 225, 240, 241
- NADH dehydrogenase gene 149
 NADH-ubiquinone oxidoreductase 81–85
 Netherlands, BD severity 210–12
 neuregulin 1 (NRG1) 150–51
 neurobiology of BD 8, 209
 kindling/sensitization model 209, 213, 215
 stages of illness and 209
 neurochemical brain imaging 105–6
 MRS 106
 pediatric BD 225
 radiotracer methods, receptor density 105–6
 neurocognitive findings in BD 169–83
 clinical course impact 182–83
 cognitive domains *see* cognitive domains
 comorbid psychiatric illnesses and 180–81
 late life BD 235–36
 mood state impact 182
 peer-reviewed journals, increase 169
 psychotropic drug effects 181, 183
 summary of findings 182 *see also* cognitive changes/impairment in BD
 neurodegeneration 237–38, 276
 neurodevelopment
 DNA methylation of genes 155
 gene association studies 146, 149–51
 BDNF 150
 DISC1 151
 NRG1 150–51
 insult effect 121–23, 149
 neurodevelopmental model 121–23, 124, 149 *see also* infectious agents/infections
 neuroendocrinology 278
 lithium effect in late life BD 240
 serotonin signaling dysfunction 44
 of stress *see* stress
 neuroimaging in BD 102–9
 catecholamine hypothesis, evidence 32
 endophenotype identification 108
 functional 104–5
 childhood and adolescence 223–24
 late life BD 239
 mindfulness-based CBT effect 196–97
 regional abnormalities 104 *see also* functional MRI (fMRI) in BD; PET/SPECT
 GABA 50, 51, 52
 glutamatergic neurotransmission 54
 historical background 102
 late life BD *see* late life BD
 neurochemical *see* neurochemical
 brain imaging
 role in BD diagnosis and management 107–9
 algorithms for diagnosis 107–8
 high risk populations and prevention 108–9
 pattern classification methods 107–8
 probabilistic classification in models 108
 treatment response prediction 109
 serotonin signaling defects 44–45, 46
 structural 102–4, 108
 childhood and adolescence 222–23
 DTI *see* diffusion tensor imaging (DTI)
 MRI *see* magnetic resonance imaging (MRI)
 neuropathology correlation 103–4
 summary and significance of findings 107
 unipolar depression vs 106–7
 white matter abnormalities 106, 135–36 *see also* individual techniques *e.g.* PET/SPECT
 neuroinflammatory changes 96–97, 259
 neurological disease, as modifier of acute efficacy of treatment 242
 of long-term outcomes 242
 neuronal changes in BD 103–4
 chronic elevation of glucocorticoids 95–96
 neuronal resilience, to oxidative stress 61–65
 neuropathology in BD 103–4
 neuroplasticity 95–96, 137–38, 260, 276
 neuroprogression in BD 236, 278
 “neuroprogressive illness” 236, 278
 neurotoxicity, cytokines, kynurenine pathway 271, 274, 276, 278
 neurotransmission, catecholamine release 22
 neurotransmitter(s)
 anticonvulsant/proconvulsant 209
 depletion, precursor depletion 26–27
 excitatory 52
 inhibitory *see* GABA (γ-aminobutyric acid)
 late life BD 240
 pathways, gene association studies 151
 receptor binding, antipsychotic drugs 261 *see also* individual neurotransmitters
 neurotrophic factors, decrease 65
 nitric oxide 54, 62
 3-nitrotyrosine 62
 NMDA receptors 52, 53, 147
 activation, DAO and 147
 antagonist 55
 antibodies 54
 entorhinal cortex 53
 hippocampus 53, 95–96, 147
 striatum 53
 non-steroidal anti-inflammatory drugs (NSAIDs) 258
 norepinephrine 21, 104
 breakdown/metabolites 22–23
 discovery and role 21
 level reduced by lithium 28
 metabolites in plasma/urine 23, 29
 synthesis 22, 23, 31
 yohimbine action 26
 normetanephrine 23
 NR1D1, gene encoding 114–15, 145, 147, 156
 NRG1 gene 150–51, 155
 nuclear factor kappa B (NF-κB) 273, 276
 nucleus accumbens, BDNF increase 210
 obesity 256, 259
 ODZ4 gene 153

- offspring of BD patients
 - HPA abnormalities and cortisol 93
 - illness onset 108
 - non-bipolar, brain structural abnormalities 108
- 8-OHDPAT 11
- olanzapine 63, 109
- omega-3 fatty acids 63
- Oppositional Defiant Disorder (ODD) 220
- ouabain, animal model of mania 13
- oxidative damage 61
- oxidative stress 61–65, 213, 240
 - BD and 61–62
 - stage-dependent factors 62
 - treatment effects 62–63
- cell membrane abnormalities due to 64–65
- definition 61
- historical background 61
- markers 62
 - in BD models 61–62
 - elevated in BD 62
 - in unipolar depression 64
- mechanisms 61
- neurotrophic factor decrease 65
- reduced by antioxidants 63
- reduced by mood stabilizers 63
- signal transduction abnormalities due to 64–65
- unipolar depression and 64
- oxidizable substrate 61
- 8-oxo-2'-deoxyguanosine (8-OHdG) 64

- P2RX7 148
- panic attacks, cocaine-induced 207–8
- Parkinson's disease 24–25
- patent laws 254
- pattern recognition analyses 226
- PBRM1 gene 153
- pediatric BD *see* childhood and adolescence
- Per1 114
- PER3 gene 114
- peripheral blood mononuclear cells 272–73, 280
 - molecular changes, signaling 273, 274
- PET imaging 104, 130
- PET/SPECT 104–5
 - catecholamine hypothesis, evidence 32
 - dopamine receptors, 32
 - dopamine transporter 32
 - GABA system 51
- pharmac-EEG 136
- pharmacogenomics 156, 263
- pharmacokinetics, late life BD 241

- pharmacological
 - interventions 250–54
 - adherence to 191, 192, 195
 - late life BD 242
 - combination regimens 251, 263
 - current status of drug treatment 250–51
 - drugs affecting clock genes 115
 - effect on melatonin levels 112
 - late life BD *see* late life BD
 - metabolic side-effects 257, 258
 - in metabolic syndrome and BD 263–64
 - monotherapy 251
 - new 250–54
 - assessment difficulties 250, 251
 - domains of behavior for assessing 250
 - future prospects 251–52
 - innovative approaches 251
 - program leadership by marketing 254
 - regulatory processes 254
 - stress response associated 97
 - Symbyax 44 *see also* drug development
 - response prediction
 - ASF-slope of LDAEPs 137
 - EEG abnormalities and 131–32, 137
 - neuroimaging 109
 - symptoms and functional impairment despite 191
 - underuse of domain profiles of treatments 252–54
 - inductive inference
 - application 253
 - patient selection 253
 - production business model
 - misapplied 253–54
 - statistical challenges 252–53
 - study designs inconsistent with practice 253–54
 - time to event analyses 253
- phenotypes, quantitative trait loci 154–55
- phosphoinositide 3 kinase (PI3K) 146, 147–48
- phospholipid membrane, assessment 106
- physical activity 260
- pindolol 136
- pituitary gland, volume in BD 95
- plasma
 - catecholamine hypothesis evidence 29
 - dopamine levels 23–24
 - GABA levels 50
 - norepinephrine/epinephrine levels 23

- PME (phosphomonoester) 106
- poly(I:C) 121–22
- Porsolt (forced swim) test 9, 10
- positive predictive value (PPV) 108
- postmortem brain studies 30, 276
 - catecholamine hypothesis evidence 30–31, 32
 - catecholamine metabolites, effects of death 30, 31
 - circuitry-specific hypermetabolism *see* hippocampus
 - GABA system abnormalities 49–50
 - gene expression changes 30–31
 - glutamate *see* glutamatergic neurotransmission
 - abnormalities
 - limitations 30
 - metabolomic studies 31
 - mitochondrial dysfunction 62
 - serotonin metabolite levels 46
 - structural neuroimaging correlation 103–4
 - tissue quality 30
 - predictive validity 8, 9
 - prefrontal cortex in BD
 - amygdala connectivity in pediatric BD 225
 - children and adolescents 222–24, 225
 - decreased TNF- α receptor 2 276
 - functional neuroimaging 104, 105
 - general intellectual functioning 179
 - glial cell changes 104
 - NAA levels 225
 - protein oxidation and 3-nitrotyrosine 62
 - remodeling, glucocorticoid elevation 96
 - unipolar depression vs 106
- Pre-pulse inhibition (PPI) 14
- prevalence of BD 8
 - in metabolic syndrome 256, 258
- prevention of BD
 - children 215
 - early stage of illness 214–15
 - influenza vaccine role 126
 - neuroimaging role 108–9
- prevention of metabolic syndrome 262–63
- primate models 10, 120
- primate separation model 10
- “primordial emotions” 91
- problem solving *see* reasoning and problem solving
- processing, speed *see* speed of processing (cognition)
- prodrome of BD 208
- progression of BD 205–6, 211, 212
 - feedback cycle 211

Index

- late life BD 236
- neuroprogression 236, 278
- non-specific mechanisms 213
- as stage VI 208
- staging 208–9
- prolactin 44, 112
- protein, oxidation 62
- protein-activated kinase 7 (PAK7) 154
- protein synthesis, upregulation 70
- psychiatric disorders 144, 180–81, 269
- psychoeducation 192, 193, 196
 - CBT *vs* 193–94
 - stage of illness 214
- psychoneuroimmunology 121
- psychopharmacology, kindling/
 - sensitization model 209–10
- psychosis
 - anti-NMDA receptor antibodies 54
 - CA3/2 abnormalities
 - (hippocampus) 86
 - continuum of BD and schizophrenia 121, 144
 - DAOA as candidate gene 147
 - gene linkage studies 145
- psychosocial functioning 191
- psychosocial interventions, late
 - life BD 243
- psychosocial stress 96, 206, 238
- psychostimulants 13, 204, 207–8
- psychotherapeutic
 - interventions 191–99
 - approaches/modalities 192
 - biological concomitants 195–97
 - bipolar *vs* unipolar
 - depression 197–99
 - CBT *see* cognitive behavior therapy (CBT)
 - comorbidities (of BD) 195
 - dose–response relationship 199
 - early intervention, focus 195
 - family interventions 194–95
 - goals 191
 - historical overview 191–95
 - interpersonal and social rhythm therapy (IPRST) 192–93, 198
 - kindling/sensitization model
 - and 212–13
 - neuroimaging 196
 - non-specific effects 197
 - psychoeducation *vs* 192
 - randomized controlled trials
 - 191–92, 193, 194, 197, 214
 - unipolar *vs* bipolar
 - depression 198–99
 - recurrence prevention 195
 - stage of illness and
 - effectiveness 214
 - psychotic disorders, DSM-5 2
 - psychotropic drugs 181, 183
 - quantitative trait loci (QTL) approach
 - 12, 154–55
 - quinpirole 13
 - radiotracer techniques 105–6
 - rapid-cycling BD 92, 206, 207
 - rapid eye movement (REM)
 - sleep 113
 - reactive oxygen species (ROS) 64
 - negative effects in depression 65
 - positive roles 64, 65
 - reasoning and problem solving
 - 177–79, 182
 - brain regions 178
 - clinical course impact 179
 - evidence for impairment in
 - BD 178–79
 - measures/assessment 177–79
 - mood state effect 179
 - reconsolidation window 212–13
 - recurrence of BD 208, 211
 - faster, kindling model
 - evidence 207
 - psychosocial stressors 206
 - Reelin 121
 - regulations, drug development 254
 - remission, cortisol levels 93
 - Research Domain Criteria (RDoC)
 - (NIMH) 1, 2, 6, 225
 - resident–intruder test 14
 - response inhibition 222, 224
 - response to treatment *see*
 - pharmacological interventions
 - resting-state functional connectivity
 - MRI 105
 - reversal learning,
 - impairment 222, 224
 - reverse translation of behavioral traits
 - 13, 14, 15
 - reward, behavior and 222
 - riluzole 55
 - risk factors
 - genetic *see* genetic factors in BD
 - etiology
 - metabolic syndrome 256, 258
 - schizophrenia and BD,
 - shared 153
 - [¹¹C]-Ro15-4513 51
 - rodent models *see* animal models/
 - studies
 - rubella 123
 - schizoaffective disorder
 - bipolar type (SABP) 50
 - infectious agents and *see* infectious
 - agents/infections
 - schizophrenia
 - auditory ERP abnormalities 133
 - BD *vs.* sensory ERP
 - abnormalities 134–35
 - bipolar disorder I and 2
 - candidate genes, DAOA 147
 - continuum of BD and 121,
 - 144, 153
 - gene linkage studies 145
 - genome-wide association
 - studies 153
 - infectious agents and *see* infectious
 - agents/infections
 - lateral ventricle enlargement 102
 - mitochondrial gene expression
 - changes 149
 - neurodevelopmental model 121
 - seasonal births 120
 - seasonal symptoms 111, 115
 - seizures
 - drug-induced 207, 208
 - kindling 204, 206–7, 208, 209
 - selective serotonin reuptake inhibitors
 - (SSRIs) 43
 - sensitization
 - animal models 204, 205, 207–8
 - behavioral *see* behavioral
 - sensitization
 - to stressors 204, 205, 206, 210–11
 - childhood 207, 210
 - cross sensitization 208–9,
 - 210–11, 215–16
 - see also* kindling/sensitization
 - (K & S) model
 - Sequential Multiple Assignment
 - Randomized Treatment
 - (SMART) 253
 - serotonergic dysfunction 43–46, 276
 - serotonin (5-HT)
 - BD pathophysiology 276
 - cytokine-mediated changes 276
 - functions 43
 - bipolar symptoms
 - associated 43
 - hormones stimulated by 44
 - kynurenine pathway
 - and 276, 277
 - metabolites in CSF and brain
 - tissue 46
 - receptors *see* 5-HT_{1A} receptors;
 - 5-HT_{2A} receptor
 - synthesis 43
 - serotonin-based medications
 - bipolar *vs* major depressive
 - disorder 43–44
 - for mania 44
 - serotonin norepinephrine
 - reuptake inhibitors
 - (SNRIs) 43, 276
 - serotonin signaling
 - dysfunction 43–46

- comorbidities and medication effects 46
- CSF and postmortem studies 46
- future research directions 46
- neuroendocrine studies 44
- neuroimaging studies 44–45, 46
- pharmacological studies 43–44
- signaling deficit
 - depression symptoms 43
 - mania symptoms 43
- signaling elevation
 - mania symptoms 43
 - neuroendocrine studies 44
- serotonin transporter
 - blockade 45
 - SSRIs and SNRIs 43
- serotonin transporter (5-HT transporter) 45, 105
 - blockade by serotonin-based medications 43, 45
 - DNA methylation 155
 - gene variants 45–46, 151, 156
 - internalization rate 45
 - levels in depressed phase, neuroimaging and 45
 - lithium response and gene variants 156
 - in prefrontal cortex, levels 46, 105
- “Severe Mood Dysregulation” (SMD) 219–20
- “sickness behavior” 270
- signaling cascades/transduction
 - immune-related 273, 274
 - mood stabilizers effect 54
 - oxidative stress causing dysfunction 64–65
 - relationships of key molecules 157
- “single neurotransmitter, single disease” hypotheses 35
- single-nucleotide polymorphisms (SNPs) 145, 154, 155
 - mitochondrial genes 149
- sleep 113
 - cognitive alteration in BD 113
 - decreased need in mania 113
 - deprivation 55, 113
 - animal models 13–14, 15
 - disturbances in depression 113
- sleep–wake cycles 113
 - manipulation 115
- SPECT imaging 104 *see also* PET/SPECT
- speed of processing (cognition) 171–73, 182, 235
 - clinical course impact 172–73
 - evidence for impairment in BD 172
 - measurement 172
 - models, and factors affecting 172
 - mood state effect 172
- stages of BD
 - kindling/sensitization
 - model 208–9
 - interventions effect 206, 209, 214
 - psychotherapy effectiveness 214
 - treatment 214–15
- staging BD progression 208–9, 278
 - clinical/biological markers (stages 0–4) 279
 - sensitization/kindling model 209
- statistics, limitations of treatment studies 252–53
- stem cells, pluripotent 158
- STEP-BD study (Systematic Treatment Enhancement Program for Bipolar Disorder) 44, 198–99
- stress 90–97
 - after BD diagnosis 191
 - BDNF Met allele and 156
 - chronic exposure
 - animal model 9, 10–11
 - BD and comorbidities link 278
 - inflammatory response
 - role 96–97
 - depression onset association
 - 90, 155–56
 - failure to recover from neuronal microdamage due to 97
 - learned helplessness animal model 9, 11
 - neuroinflammatory effects 96
- stressors
 - in childhood, kindling/sensitization model 207, 210
 - cross sensitization in BD 208–9, 210–11, 215–16
 - environmental 126, 155–56, 157
 - infectious 126
 - sensitization *see* sensitization
- stress responses 91
 - appraisal phase 91
 - gene association studies 94–95, 146, 148–49
 - glucocorticoid receptors and 90, 93–94, 278
 - glucocorticoids/inflammatory response interplay 96–97
 - HPA axis and *see* hypothalamic–pituitary–adrenal axis (HPA)
 - neurophysiology 91–92 *see also* cortisol; glucocorticoid receptors (GRs)
 - volume differences in neuroendocrine brain areas 95
- striatum 53
 - in pediatric BD 223–24
- stroke *see* cerebrovascular disease
- substance abuse 195, 236
 - drug efficacy affected by 242
 - neurocognitive impairment 180
 - sensitization, stressor interaction 208–9, 210–11
- substance-induced mania, DSM-5 and 1, 4–5
- suicidal attempts, 5-HT_{1A} receptor levels and 45
- suicide risk 114, 243
- superoxide dismutase (SOD) 61
 - bipolar depression 62, 63
 - unipolar depression 64
- suprachiasmatic nucleus (SCN) 111–12, 116
- sweet solutions, animal model preference 10, 14
- Symbyax 44
- symptoms
 - bipolar I disorder 8
 - depression in BD 43
 - hypomania 5
 - inflammation interactions, mechanisms 259
 - mania 43
 - manic, due to drugs of abuse 5
 - mixed episodes/states 3, 4
 - pediatric BD 219
 - in pharmacological intervention studies 250
 - seasonal 111, 115
 - serotonin function associated 43
- tail suspension test (TST) 9, 10, 11, 12
- T cells in BD 273
 - regulatory (Treg) 273
- telomeres 213, 215
- temperature (body) 111
- temporal lobe, dysfunction/changes 103, 181
- temporal lobe epilepsy 131
- temporal neocortex, glucocorticoid receptors 93
- thermogenesis 261–62
- thyroiditis, autoimmune 272
- thyrotropin 112
- thyrotropin-releasing hormone (TRH) 208, 209
- tolerance to treatments 209–10, 241
 - modifiers of tolerability 241
 - reversal 209–10
- top-down processing 170, 222–23
- Tower of London task 178, 179
- Toxoplasma gondii* 124, 125
- Translocator Protein (TSPO)
 - gene 94–95
- treatment-induced mania *see* mania

Index

- treatment of BD
 drug therapy *see* pharmacological interventions
 early stage, importance 213, 214–15
 immune-based strategies 279–80
 kindling/sensitization model *see* kindling/sensitization (K & S) model
 late-life BD *see* late-life BD
 later stages 214
 psychotherapy *see* psychotherapeutic interventions
- treatment resistance 208, 256, 258
- tryptophan 44
 depletion 27
 elevated breakdown in BD 259
 metabolism, kynurenine pathway 276, 277
- tryptophan hydroxylase 43
- TSPO* gene polymorphism 94–95
- tumor necrosis factor- α (TNF- α) 270, 273, 275
 gene variant, in BD 271
 inhibitors 258
 neuroprogression in BD and 278
 receptor type 1 (sTNFR1) 274–75, 278
 trans-membrane, increased in BD 276
- twin studies 108, 144, 271
 DNA methylation 155
 ERP abnormalities as endophenotype 134
 gene association studies 148
 verbal memory deficit 235
 “two-hit” hypothesis 126, 156, 237
- tyrosine depletion 26, 27
- tyrosine hydroxylase 22, 27, 31
- unipolar depression
 antioxidant benefits 64
 depression in BD *vs see* depression in BD
 infectious etiology role *vs* BD 126
- oxidative stress 64
- stressor sensitization and 207
- urine
 catecholamine levels 29
 dopamine levels 23–24
 norepinephrine/epinephrine levels 23, 28
 USA, BD severity 210–12
- validity
 construct 8, 9, 15
 predictive 8, 9
- valproate
 dopamine, receptors and synthesis 29
 effects on catecholamine activity 29
 efficacy affected by neurological disorders 242
 GABA and GABA transporter levels 51–52
 glutamatergic neurotransmission 54
 as histone deacetylase inhibitor 213
 oxidative stress decrease 63
 pro-inflammatory cytokine stimulation 279
 treatment response prediction 109
- vanillyl mandelic acid (VMA) 22, 23, 29
- vascular factors, late life BD 237
- VCAM (vascular cell adhesion molecule) 275, 277
- velocardiofacial syndrome 151, 154
- verbal fluency 172
- verbal learning and memory *see* learning and memory, verbal
- vesicles, catecholamine leakage/release 22
- vesicular monoamine transporter 2 (VMAT2) 32
- vigilance *see* attention/vigilance
- viral infections
 maternal, BD aetiology 120–21
- schizophrenia risk 123–24 *see also* influenza virus, maternal infection
- vulnerability to BD 208, 210
- weight gain, second-generation antipsychotics 261, 262
- Wellcome, Henry 253–54
- white matter changes, in BD 96, 135–36
 hyperintensity (WMH) 106, 236, 238–39
- Wisconsin Card Sorting Test (WCST) 177–79
- Wnt signaling pathway 146, 147–48
- working memory 173–75, 179
 antipsychotic drugs impairing 175, 181
 assessment measures 173, 174
 circuitry of regions 85
 clinical course impact 174–75
 cognitive remediation effect 196
 “executive”, reasoning/problem solving *vs* 177
 impairment in BD 95, 105, 171, 182
 evidence for 173–74, 196
 glucocorticoids role 95
 mood state effect 174, 182
 organization 173
 verbal information 173
 visuospatial information 173, 174
- XBP1 gene 148–49
- yohimbine 26
- zebularine 210
- zinc supplement, unipolar depression 64
- ZNF804A gene 153, 154, 155
- zolpidem 50
- zonisamide 251
- ‘Z’ type sedatives 49